NasdaqCM - Nasdaq Real Time Price USD

Scilex Holding Company (SCLXW)

Compare
0.2375 +0.0075 (+3.30%)
As of 1:19 PM EDT. Market Open.
Loading Chart for SCLXW
DELL
  • Previous Close 0.2300
  • Open 0.2101
  • Bid --
  • Ask --
  • Day's Range 0.2100 - 0.2832
  • 52 Week Range 0.2100 - 0.2832
  • Volume 30,066
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.16
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.

www.scilexholding.com

113

Full Time Employees

--

Fiscal Year Ends

Recent News: SCLXW

View More

SCLX Grows Sales and Improves Finances

Compare To: SCLXW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SCLXW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -233.88%

  • Return on Assets (ttm)

    -53.64%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    50.83M

  • Net Income Avi to Common (ttm)

    -171.53M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.89M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    57.29M

Company Insights: SCLXW

People Also Watch